Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v2.4.0.8
Condensed Consolidated Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Revenues:    
Royalties $ 7,850 $ 5,826
Material sales 5,715 1,539
Collaborative research and development and other revenues 2,393 4,286
Total revenues 15,958 11,651
Operating costs and expenses:    
Cost of sales 2,451 663
Research and development 3,131 2,465
General and administrative 5,072 4,502
Lease exit and termination costs 204 89
Total operating costs and expenses 10,858 7,719
Income from operations 5,100 3,932
Other (expense) income:    
Interest expense, net (248) (912)
Increase in contingent liabilities (1,948) (1,841)
Other, net (754) 191
Total other expense, net (2,950) (2,562)
Income before income taxes 2,150 1,370
Income tax expense (53) (66)
Income from continuing operations 2,097 1,304
Discontinued operations:    
Gain on sale of Avinza Product Line before income taxes 0 191
Income from discontinued operations 0 191
Net income: $ 2,097 $ 1,495
Basic per share amounts:    
Income (loss) from continuing operations (in usd per share) $ 0.10 $ 0.06
Income from discontinued operations (in usd per share) $ 0.00 $ 0.01
Net income (loss) (in usd per share) $ 0.10 $ 0.07
Diluted per share amounts:    
Income (loss) from continuing operations (in usd per share) $ 0.10 $ 0.06
Income from discontinued operations (in usd per share) $ 0.00 $ 0.01
Net income (loss) (in usd per share) $ 0.10 $ 0.07
Weighted average number of common shares-basic (in shares) 20,600,683 20,189,378
Weighted average number of common shares-diluted (in shares) 21,208,023 20,280,030